ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 185.10K | 204.30K | 307.00K | 47.40K | 219.20K |
| Depreciation & Amortization | 7.60K | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 224.60K | 237.20K | 394.20K | 108.00K | 268.20K |
| Operating Income | -224.60K | -237.20K | -394.20K | -108.00K | -268.20K |
| Income Before Tax | -219.10K | -227.90K | -364.00K | -106.80K | -251.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -219.10K | -227.90K | -364.00K | -106.80K | -251.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -219.10K | -227.90K | -364.00K | -106.80K | -251.30K |
| EBIT | -224.60K | -237.20K | -394.20K | -108.00K | -268.20K |
| EBITDA | -223.80K | -237.10K | -394.20K | -108.00K | -268.20K |
| EPS Basic | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 25.19M | 25.20M | 25.09M | 23.59M | 23.56M |
| Average Diluted Shares Outstanding | 25.19M | 25.20M | 25.09M | 23.59M | 23.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
